Dr Abdul Mannan: CVT Risk With CHC is Not One-Size-Fits-All
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“CVT risk with CHC is not one-size-fits-all. The type of progestin matters enormously (fourth-generation worst), and the multiplication of risk factors (family history, thrombophilia, obesity) creates scenarios with 200+ fold increased risk.
Most important clinical change:
Take family history more seriously – it predicts risk independently of thrombophilia testing. And if you’re prescribing CHC, think twice about fourth-generation progestins.
The absolute risk remains low for most women, but for that high-risk subset (family history + thrombophilia), the numbers are sobering enough to have serious conversations about alternative contraception.”
Title: The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
Authors: Maria Abbattista, Addolorata Truma, Ida Martinelli, Francesca Gianniello, Serena M. Passamonti, Marco Capecchi, Andrea Artoni, Flora Peyvandi, Paolo Bucciarelli

Read full article here.
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 08:43Joy Duemke: Optimizing Stem Cell Collection for Gene Therapy Success
-
Jul 21, 2026, 07:55A New Era of Precision Imaging for Venous Thromboembolism – JTH
-
Jul 21, 2026, 07:43How to Monitor and Manage Unfractionated Heparin in Practice – JTH
-
Jul 21, 2026, 07:23Arthur Allen: Advancing Outpatient Antithrombotic Stewardship Through ADAPT
-
Jul 21, 2026, 03:19Where Does Stroke Treatment Go Next on The Latest ESOC 2026 TV Studio Session – ESO
-
Jul 21, 2026, 03:09Francesca Palandri: New Insights Into Anemia Management in Myelofibrosis
-
Jul 21, 2026, 01:57A New Approach to Understanding Plasmin Generation and Fibrinolysis – RPTH Journal
-
Jul 21, 2026, 01:52Maria Diaz Alonso: Delivering My First International Oral Presentation at ISTH 2026
-
Jul 21, 2026, 01:44Megan Preece: Presenting New Research on Antiphospholipid Syndrome at ISTH 2026